Bayer and Onyx Initiate Phase III Trial of Nexavar® in Non-small Cell Lung Cancer
- Details
- Category: Bayer
Bayer HealthCare AG and Onyx Pharmaceuticals, Inc. have begun enrolling patients in an international Phase III trial to evaluate Nexavar® (sorafenib) tablets in patients with non-squamous non-small cell lung cancer (NSCLC) who have failed two or three previous treatments.
Bayer and Onyx Initiate Phase III Trial of Nexavar® in Non-small Cell Lung Cancer
- Details
- Category: Bayer
Bayer HealthCare AG and Onyx Pharmaceuticals, Inc. have begun enrolling patients in an international Phase III trial to evaluate Nexavar® (sorafenib) tablets in patients with non-squamous non-small cell lung cancer (NSCLC) who have failed two or three previous treatments.
Abbott Named One of the Top 10 Companies for Scientists
- Details
- Category: Abbott
Abbott was recently named one of the Top 10 companies on The Scientist magazine's "Best Places to Work in Industry" list. Abbott was ranked No. 6 on the list of Large Companies (more than 5,000 employees). This is the sixth time that Abbott has been on the list since The Scientist first started ranking companies in 2003. This prestigious list is based on a detailed survey of scientists at life-science companies and research institutions worldwide.
AstraZeneca Regulatory Update on Seroquel XR for the Treatment of Major Depressive Disorder
- Details
- Category: AstraZeneca
AstraZeneca today announced that the company has referred its application for SEROQUEL XR (quetiapine fumarate) Extended Release Tablets for the treatment of recurrent depressive episodes in adult patients with major depressive disorder (MDD) to the Committee for Medicinal Products for Human Use (CHMP; a scientific committee of the European Medicines Agency, EMEA).
Phase III Trial Started to Evaluate Combination Therapy of Nexavar® and Tarceva®
- Details
- Category: Bayer
Bayer HealthCare AG, Onyx Pharmaceuticals, Inc., OSI Pharmaceuticals, Inc. and Roche announced the initiation of a Phase III trial examining Nexavar® (sorafenib) tablets in combination with Tarceva® (erlotinib) tablets as a potential new treatment option for
patients with advanced hepatocellular carcinoma (HCC), or primary liver cancer.
Nycomed Reports a Solid Start to 2009
- Details
- Category: Nycomed
Nycomed reports a solid start to 2009, with total net turnover increasing by 1.2% to €839.9 million, despite adverse impact from currency movements. Excluding the effects of currency, the increase was 3.8%, underlining the solid performance of the main product Pantoprazole and other key products. On a regional basis, most Nycomed markets performed in line with or above expectations.
US Department of Health and Human Services (HHS) purchases GSK's A (H1N1) influenza antigen
- Details
- Category: GlaxoSmithKline
The US Department of Health and Human Services (HHS) has placed initial orders for GSK's A (H1N1) influenza vaccine antigen and the company's proprietary adjuvant system, AS03, to support its pandemic influenza preparation efforts.
More Pharma News ...
- Roche announces new two-year data from the LITHE study
- Sandoz to acquire EBEWE Pharma specialty generics business
- Abbott's XIENCE V(R) Demonstrates Impressive Results in SPIRIT V Study
- Pfizer Expands Its Generics Portfolio
- Sanofi-aventis introduces sanofi-aventis TV "A window on our company"
- Nexavar® Approved in Japan for the Treatment of Advanced Liver Cancer
- Lilly and Medtronic Form Alliance to Provide Solutions for Diabetes Management